SCHEMBL14770648

SCHEMBL14770648

c1ccc(-c2cc(-c3cncc(-c4ccc5oc6ccc(-n7c8ccccc8c8ccccc87)cc6c5c4)c3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.36
PLA2G2A P14555 3/20 0.33
PLA2G4A P47712 3/20 0.33
KDM4E B2RXH2 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
ATM Q13315 1/20 0.33
PLA2G10 O15496 1/20 0.33
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PGR P06401 2/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
BTK Q06187 3/20 0.33
PIK3CD O00329 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
PIK3CG P48736 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733754 0.93 KDM4E (0.38) CYP19A1PLA2G2APLA2G4AKDM4EL3MBTL1
SCHEMBL14770600 0.92 CYP19A1 (0.37) CYP19A1PLA2G2APLA2G4AKDM4EL3MBTL1
SCHEMBL10041333 0.90 KDM4E (0.38) PLA2G2APLA2G4AKDM4EL3MBTL1ALDH1A1
SCHEMBL14770665 0.88 BTK (0.38) CYP19A1PLA2G2APLA2G4AKDM4EL3MBTL1
SCHEMBL14770664 0.88 KDM4E (0.34) PLA2G2APLA2G4AKDM4EL3MBTL1ALDH1A1
SCHEMBL14770662 0.88 BTK (0.38) CYP19A1PLA2G2APLA2G4AKDM4EL3MBTL1
SCHEMBL14770667 0.88 PLA2G2A (0.39) PLA2G2APLA2G4AKDM4EL3MBTL1ALDH1A1
SCHEMBL14770734 0.87 KDM4E (0.38) PLA2G2APLA2G4AKDM4EL3MBTL1ALDH1A1
SCHEMBL14770702 0.87 KDM4E (0.38) PLA2G2APLA2G4AKDM4EL3MBTL1ALDH1A1
SCHEMBL14770647 0.87 PLA2G2A (0.32) PLA2G2APLA2G4AKDM4EL3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND TDO2, AHR, NOC2L CYP19A1 208/4885PLA2G2A 4744/4885PLA2G4A 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.